Statistical Vision has been rebranded as Hahn Stats. Image via Getty Images

Statistical Vision, a Houston-based data and analytics firm, has been scooped up by Austin-based marketing and communications agency Hahn Public for an undisclosed amount.

The deal expands Hahn Public to a 48-person agency with combined annual revenue exceeding $10 million. Statistical Vision has been rebranded as Hahn Stats.

“Our clients come to us drowning in data — sales transactions, marketing information, commodity prices, import and export data, demographics, weather forecasts, etcetera,” Michael Griebe, co-founder and chief statistical officer of what now is Hahn Stats, says in a news release. “We build predictive analytic models to answer specific questions and to point our clients towards revenue growth.”

Griebe and Dirk Van Slyke founded Statistical Vision in 2014. The company's local office is at The Cannon West Houston. Hahn Stats LLC also has an office in Denver.

The data and analytics prowess developed by Statistical Vision will benefit Hahn Public clients like Houston-based ZTERS, Whataburger, the Texas Department of Agriculture, Beef-Loving Texans, H-E-B’s Central Market, Vital Farms, the Propane Education & Research Council, OneGas, GPA Midstream, the East Texas Electric Cooperative, and the Northeast Texas Regional Mobility Authority.

Jeff Hahn, principal of Hahn Public, says the acquisition of Statistical Vision and its data and analytics capabilities will help Hahn Public’s array of food and energy clients, who “continue to face a rapidly changing and uncertain landscape.”

Other businesses under the Hahn umbrella are Apron Food & Beverage Communications, Predictive Media Network, and White Lion Interactive.

Statistical Vision shares key data points it's watching as companies return to work amid the COVID-19 outbreak. Getty Images

Houston data startup analyzes COVID-19 risks as companies return to work

Guest column

In an effort to better help our clients, and frankly all of us, maneuver these uncertain times and to better understand what the upcoming months are likely to bring, we have applied our data science expertise to create a structural model of the spread of COVID-19. The aim of the national model is to determine specifically how mobility and weather impact the local transmission rates while controlling for population density, population immunity rate and the fact that people are taking more precautions.

When I discuss COVID19 with other Houstonians, I'm often asked "We're going back to work — there's traffic! Why haven't cases spiked?"

First, it is worth noting that cases and deaths have increased again in Harris County. But, the question is still valid. Greg Abbott started allowing things to open six weeks ago and we are only starting to see a rise now.

Fortunately, our model (being quantitative and multivariate) can explain why cases may not have 'spiked' the way that was expected. There are four main reasons why cases are only starting to tick up now:

  1. There has not been a 'spike' in people leaving their homes. While Greg Abbott did allow restaurants, movie theaters and malls to begin re-opening on April 30, there was not a sudden spike in people leaving their homes. Indeed, the "people staying home" index, according to Google Mobility Data, peaked on April 1 at 22 percent above normal and has gradually decreased ever since. In Harris County, the extent people are staying at home stands at 14 percent above normal as of May 29 (unfortunately, Google Mobility Data reports 7 to 10 days after the fact.) So, from the peak 'stay at home' measure, we were only a third the way back to normal last week.
  2. Temperatures have increased. Our model indicates that warmer temperatures decrease the transmission rate of COVID19. Our model does not posit a mechanism, but we can rule out both geographic explanations and behavioral explanations, which leaves us with the compelling reason to believe that temperatures matter.
  3. People's behaviors when they do go out have changed. These changes — everything from masks, to skipping hand shakes, to readily available hand sanitizer, to keeping your distance, to staying home when you're feeling sick — have an important and measurable impact on the spread.
  4. Kids are not back in school yet. While our model does not directly measure the impact of kids being in school, the estimate our model produces measuring the importance of staying at home (2.6) is higher than they should be (2, mathematically speaking). We suspect that's because we are missing an important cohort that started staying at home at the same time mobile phone users started staying at home - kids that don't have cell phones. So, while it may seem like we are most of the way back to normal, with regards to going out, being summer time in Houston, kids are not at school, which is likely keeping the rate of spread down.
All of that said, the gradual increase in people leaving their homes has had an impact. And now, cases and deaths are starting to increase. Our model reminds us that there are a variety of factors impacting the transmission rate. Right now, temperatures, people's behaviors and schools being out work in our favor. Come September, two of those three will turn the other way.
------
Michael Griebe is the co-founder and chief statistical officer at Houston-based Statistical Vision. To read more about the company's initiative, click here.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston family's $20M donation drives neurodegeneration research

big impact

Neurodegeneration is one of the cruelest ways to age, but one Houston family is sharing its wealth to invigorate research with the goal of eradicating diseases like Alzheimer’s.

This month, Laurence Belfer announced that his family, led by oil tycoon Robert Belfer, had donated an additional $20 million to the Belfer Neurodegeneration Consortium, a multi-institutional initiative that targets the study and treatment of Alzheimer’s disease.

This latest sum brings the family’s donations to BNDC to $53.5 million over a little more than a decade. The Belfer family’s recent donation will be matched by institutional philanthropic efforts, meaning BNDC will actually be $40 million richer.

BNDC was formed in 2012 to help scientists gain stronger awareness of neurodegenerative disease biology and its potential treatments. It incorporates not only The University of Texas MD Anderson Cancer Center, but also Baylor College of Medicine, Massachusetts Institute of Technology (MIT) and Icahn School of Medicine at Mount Sinai.

It is the BNDC’s lofty objective to develop five new drugs for Alzheimer’s disease and related disorders over the next 10 years, with two treatments to demonstrate clinical efficacy.

“Our goal is ambitious, but having access to the vast clinical trial expertise at MD Anderson ensures our therapeutics can improve the lives of patients everywhere,” BNDC Executive Director Jim Ray says in a press release. “The key elements for success are in place: a powerful research model, a winning collaborative team and a robust translational pipeline, all in the right place at the right time.”

It may seem out of place that this research is happening at MD Anderson, but scientists are delving into the intersection between cancer and neurological disease through the hospital’s Cancer Neuroscience Program.

“Since the consortium was formed, we have made tremendous progress in our understanding of the molecular and genetic basis of neurodegenerative diseases and in translating those findings into effective targeted drugs and diagnostics for patients,” Ray continues. “Yet, we still have more work to do. Alzheimer's disease is already the most expensive disease in the United States. As our population continues to age, addressing quality-of-life issues and other challenges of treating and living with age-associated diseases must become a priority.”

And for the magnanimous Belfer family, it already is.

3 Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes a podcast with the founder of a new venture firm, a former astronaut and recent award recipient, and a health care innovator with fresh funding.

Zach Ellis, founder and managing partner of South Loop Ventures

Zach Ellis explains on the Houston Innovators Podcast that South Loop Ventures plans to invest in promising companies from across the country and bring them into Houston's ecosystem to grow and scale. Photo via LinkedIn

Houston has a lot of the right ingredients for commercialization and scaling up companies, so when Zach Ellis moved to town to stand up a venture capital firm that made investments in diverse founders, he decided to go about it in an innovative way.

South Loop Ventures, which Ellis launched two years ago, invests in pre-seed and seed-stage startups across health care, climatetech, aerospace, sports, and fintech. While the first handful of investments, which have already been made, are into Houston-based companies, Ellis explains on the Houston Innovators Podcast that the firm plans to invest in promising companies from across the country and bring them into Houston's ecosystem to grow and scale.

"Any investor wants to feel like they are looking at the best possible investment opportunities in which to deploy capital," Ellis says on the show. "So that's reason No. 1 to cast your net as widely as possible.

"At the same time, you want to give any investment that you make greatest chances of success," he continues. "The biggest factor of success outside of the team and the capital you give them, is the customers that they can call upon. In bringing targeted companies to Houston or connecting them with Houston, you introduce the opportunity for them to achieve rapid scale and work with world-class partners very efficiently." Read more.


Toby R. Hamilton, founder and CEO of Hamilton Health Box

Dr. Toby Hamilton has secured $10 million to grow his company. Photo via tmc.edu

A Houston company that is working on a value-based model for primary care has fresh funding to support its mission.

Hamilton Health Box announced the completion of a $10 million series A funding round led by 1588 Ventures with participation from Memorial Hermann Health System, Impact Ventures by Johnson & Johnson Foundation, Texas Medical Center Venture Fund, and the Sullivan Brothers.

The company, founded in 2019 by Dr. Toby R. Hamilton, will use the funding to fuel its expansion into rural areas to help assist those living in Health Professional Shortage Areas, or HPSAs. Read more.

Ellen Ochoa, former astronaut and center director at the NASA's Johnson Space Center

Ellen Ochoa was recognized for her leadership at NASA Johnson and for being the first Hispanic woman in space. Photo via NASA

Two astronauts recently received Presidential Medals of Freedom from President Joe Biden for their leadership in space.

Ellen Ochoa, the former center director and astronaut at the NASA's Johnson Space Center in Houston, and Jane Rigby, senior project scientist for NASA’s James Webb Space Telescope, were honored at the White House on May 3.

Ochoa spent 30 years with NASA, which included being the 11th director of JSC, deputy center director of JSC, and director of Flight Crew Operations. She served on the nine-day STS-56 mission aboard the space shuttle Discovery in 1993, and became the first Hispanic woman in space. She flew four more times to space with STS-66, STS-96, STS-110, and more.

“I’m so grateful for all my amazing NASA colleagues who shared my career journey with me,” Ochoa says in a NASA news release. Read more.

Houston health care institutions receive $22M to attract top recruits

coming to Hou

Houston’s Baylor College of Medicine has received a total of $12 million in grants from the Cancer Prevention & Research Institute of Texas to attract two prominent researchers.

The two grants, which are $6 million each, are earmarked for recruitment of Thomas Milner and Radek Skoda. The Cancer Prevention & Research Institute of Texas (CPRIT) announced the grants May 14.

Milner, an expert in photomedicine for surgery and diagnostics, is a professor of surgery and biomedical engineering at the Beckman Laser Institute & Medical Clinic at the University of California, Irvine and the university’s Chao Family Comprehensive Cancer Center

In 2013, Milner was named Inventor of the Year by the University of Texas at Austin. At the time, he was a professor of biomedical engineering at UT. One of his major achievements is co-development of the MasSpec Pen, a handheld device that identifies cancerous tissue within 10 seconds during surgical procedures.

Skoda is a professor of molecular medicine in the Department of Biomedicine at the University of Basel and the University Hospital Basel, both in Switzerland. He specializes in developing treatments for myeloproliferative neoplasms, which are a group of blood diseases including leukemia.

Other recruitment grants provided by the institute to Houston-area organizations are:

  • $4 million for recruitment of Susan Bullman to the University of Texas M.D. Anderson Cancer Center. She was an assistant professor at Seattle’s Fred Hutchinson Cancer Center, where she studied the connection between microbes and cancer.
  • $4 million for recruitment of Oren Rom to the University of Texas M.D. Anderson Cancer Center. Rom is an assistant professor of pathology and translational pathobiology at Louisiana State University Shreveport.
  • Nearly $2 million for recruitment of Lauren Hagler to conduct RNA cancer biology at Texas A&M University. She is a postdoctoral scholar in biochemistry at Stanford University.

The institute also awarded grants to five companies in the Houston area:

  • $4.7 million to 7 Hills Pharma for development of immunotherapies to treat cancer and prevent infectious diseases.
  • $4.5 million to Indapta Therapeutics for the Phase 1 trial of a cell therapy for treatment of multiple myeloma and non-Hodgkin’s lymphoma.
  • $2.75 million to Bectas Therapeutics for development of antibodies and biomarkers to overcome a type of resistance T-cell checkpoint therapy.
  • $2.69 million to MS Pen Technologies for development of technology that differentiates between normal tissue and cancerous tissue during surgery.
  • $2.58 million to Crossbridge Bio for development of an antibody-drug combination to treat certain solid tumors.